PCML
NAMS icon

Pavaki Capital Management LLC’s NewAmsterdam Pharma NAMS Stock Holding History

Pavaki Capital Management LLC’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
66,600
+30,000
+82% +$989K 0.79% 27
2026
Q1 		$1.17M Buy
+36,600
New +$1.19M 0.5% 43

Other funds holding NAMS

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Pavaki Capital Management LLC's NAMS Position: Q2 2026 in Review

Pavaki Capital Management LLC increased its NewAmsterdam Pharma (NAMS) stake by 82% in Q2 2026, buying an estimated $989K and bringing the position to 66,600 shares worth $2.26M. The position accounts for 0.79% of the portfolio, ranked #27.

Pavaki Capital Management LLC first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Pavaki Capital Management LLC held 66,600 shares of NewAmsterdam Pharma worth $2.26M as of Q2 2026.
  • Pavaki Capital Management LLC bought 30,000 NewAmsterdam Pharma shares in Q2 2026, an estimated $989K.
  • NewAmsterdam Pharma made up 0.79% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #27 holding.
  • Pavaki Capital Management LLC first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.